MedTrace Logo

Effects of FXR Activation on Hepatic Lipid and Glucose Metabolism

NCT00465751 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2012-03-09

No results posted yet for this study

Summary

The purpose of this study is to determine whether chenodeoxycholic acid decreases de novo hepatic lipogenesis, hepatic fat content, hepatic triglyceride production and plasma triglyceride concentrations and improves hepatic glucose metabolism in patients with the metabolic syndrome, Familial Hypertriglyceridemia and Familial Combined Hyperlipidemia.

Conditions

  • Metabolic Syndrome
  • Familial Hypertriglyceridemia
  • Familial Combined Hyperlipidemia

Interventions

DRUG

chenodeoxycholic acid

chenodeoxycholic acid 500 mg capsules tid po

DRUG

placebo capsules

placebo capsules containing mannitol tid po

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    lead OTHER

Principal Investigators

  • Stefan Bilz, MD · Cantonal Hospital of St. Gallen

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-10-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00465751 on ClinicalTrials.gov